| Dr Carolyn Valerie Fluhart, PHD | |
|
1324 State Route 125, Ste 202, Amelia, OH 45102-0015 | |
| (513) 981-7363 | |
| (513) 779-9209 |
| Full Name | Dr Carolyn Valerie Fluhart |
|---|---|
| Gender | Female |
| Speciality | Psychologist - Clinical |
| Location | 1324 State Route 125, Amelia, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891768503 | NPI | - | NPPES |
| 5324 | Other | OH | STATE LICENSE NUMBER |
| 000000356759 | Other | OH | ANTHEM BCBS PIN |
| 251496 | Other | OH | PHCS ID NO. |
| 11485229 | Other | OH | CAQH ID |
| 272966000 | Other | OH | MAGELLAN PROVIDER NO. |
| 251496 | Other | OH | COMPSYCH ID NO. |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 5324 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Carolyn Valerie Fluhart, PHD 2903 State Route 232, Bethel, OH 45106-8220 Ph: (513) 734-1876 | Dr Carolyn Valerie Fluhart, PHD 1324 State Route 125, Ste 202, Amelia, OH 45102-0015 Ph: (513) 981-7363 |
News Archive
The Swedish biotech company Karo Bio today announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration's lead investigational drug candidate, MK-6913, identified as part of their joint research collaboration. No milestone payment to Karo Bio is associated with the initiation of phase II clinical development.
Beth Israel Deaconess Medical Center has received a four-year, $20 million grant from the Bill & Melinda Gates Foundation to evaluate and test broadly neutralizing monoclonal antibodies for the treatment of HIV.
A new, lifesaving product aimed at reducing the death toll from heroin abuse — developed by a professor at the University of Kentucky College of Pharmacy — is in its final round of clinical trials and has received Fast Track designation by the Food and Drug Administration.
Ajinomoto Althea, Inc., a leading provider of biopharmaceutical contract development and manufacturing services, recently announced it is expanding its existing biological drug product manufacturing operations to include highly active materials such as Antibody Drug Conjugates (ADCs).
The proportion of all substance abuse treatment admissions of those aged 12 and older involving abuse of prescription pain relievers rose by over 400 percent from 2.2 percent in 1998 to 9.8 percent in 2008 according to a new study be the Substance Abuse and Mental Health Services Administration (SAMHSA). This dramatic rise in the proportion of admissions associated with the abuse of these drugs occurred among nearly all segments of the population regardless of age, gender, educational level and employment status.
› Verified 7 days ago